Healthcare

#Genolier Innovation Hub #Healthcare #Switzerland

Opening of the Genolier “centre of excellence” campus 2024 

In September 2024, DDW’s Megan Thomas attended the opening of the Genolier Campus, a campus that includes the Clinique de Genolier, the Genolier Innovation Hub, the Clinique Nescens and the Swiss Visio Network. The campus is dedicated to medical research, innovation and the training of healthcare professionals.   The hub has… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Big pharma #BioNTech #Biopharmaceuticals #Comirnaty #Covid-19 #Drug discovery #Healthcare #Moderna #mRNA #Pfizer

New podcast on drug discovery trends

This is the latest episode of the free DDW narrated podcast, “Drug discovery trends: From regulation to embracing AI”, which covers two articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: From the Editor: Law and order and… Read More

#News

#Healthcare #Life sciences #NHS #Revvity #UK

Revvity opens Scientific Centre of Excellence for genomics

Global health science solutions company Revvity, PerkinElmer’s Life Science and Diagnostics business’ new name and branding, has announced the establishment of a Scientific Centre of Excellence in Cambridge, UK.   Focused on driving genomic insights to accelerate therapeutic discovery, Revvity’s Scientific Centre of… Read More

#News

ESG cloud icon green earth concept for environment
#Clinical trials #Diversity #ESG #Healthcare #ICON

Exclusive insight from ICON Cares 2022 ESG Report 

ICON, a healthcare intelligence and clinical research organisation, recently released its ICON Cares 2022 Environmental, Social and Governance (ESG) Report. Diarmaid Cunningham, Chief Administrative Officer at ICON, shares insight with DDW.  At ICON, we engage with our key stakeholders through a variety of methods and the environmental, social and governance… Read More

#Business & Investment #Exclusive Content #Regulatory

UK
#ABPI #Healthcare #NHS #The King's Fund #UK

UK performs poorly on adoption of new drugs, report shows

The UK spends less on medicines, has a lower adoption of new drugs and poorer health outcomes compared to other similar countries, according to a new report. The King’s Fund report, commissioned by the Association of the British Pharmaceutical Industry (ABPI), gives the UK’s NHS a… Read More

#News

#Data #Drug development #Gene sequencing #Genome sequencing #Genomics #Healthcare #Precision medicine #Trusted research environment

Why Trusted Research Environments are key to the future of genomics  

Genomics is driving a revolution in drug development and, in the long run, the state of public healthcare. Advances in sequencing are leading to scientific breakthroughs in preventative care, faster diagnoses, and proactive medical interventions. Jack Dix, Head of Healthcare Strategy and Consulting at Kainos, expands.  Genetic insights are also… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Cancer research #Clinical trials #Healthcare

Improving clinical trials through patient experience

Stitch Health is a London-based start-up, on a mission to improve clinical trials by measuring and surfacing each patient’s experience. DDW’s Megan Thomas caught up with Jonathan Moshinsky, Co-Founder and CEO.  MT: Near the end of 2022, Stitch closed £2.5 million seed funding to create the definitive patient retention platform… Read More

#Business & Investment #Exclusive Content #Start-up Zone

Year change from 2022 to 2023
#Clinical trial #Clinical trial design #Covid-19 #Drug delivery #Drug development #Healthcare

Drug discovery predictions: Analysis and insight 

In January 2022, DDW’s Megan Thomas spoke to decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector. As we head into 2023, DDW will be publishing a series of reflections on these predictions. Here, Thomas reflects specifically on Anita Cooper’s prediction relating to… Read More

#Exclusive Content #Opinion #Trends & Analysis

#AI / data analytics / healthtech / informatics #Clinical trials #Covid-19 #Drug development #Healthcare #Public health #Regulatory

Drug development practices to improve public health policy 

Dr Andrew Garrett, Executive Vice President of Scientific Operations at ICON, explores the benefits of integrating some of the validation and standardisation practices already developed for PIs into the practices around NPIs and public health data; outlines some of the practices that can be implemented in order to do this;… Read More

#Exclusive Content #Opinion #Regulatory

#Drug discovery #Events #Genesis 2022 #Healthcare #Life sciences

Comment: Looking ahead to Genesis 2022 

The annual Genesis conference will take place on 7 December 2022 in London, and 5,6 and 8 December online, bringing key opinion leaders, investors and innovators from across the life sciences sector under one roof to exchange insights, debate trends and generate deals. DDW’s Megan Thomas will be in attendance… Read More

#Exclusive Content

#Drug discovery #Genetic study #Health research programme #Healthcare #NHS #Predictive diagnostics #Public health

How Our Future Health will impact drug discovery 

Recently, DDW reported on how over three million people have been invited to join Our Future Health. Andrew Roddam, CEO of Our Future Health, shares the impact research programmes such as this will have on drug discovery.  Millions of people in the UK and around the world spend many years… Read More

#Exclusive Content #Opinion

#Data #Diagnostics #Genetics / genomics #Healthcare #Public health #Rare disease #Whole genome sequencing

Personalising WGS doubles diagnosis of rare diseases 

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases.  Context   In 2018, the UK’s department of health announced an NHS Genomic Medicine… Read More

#News

Genomics
#Biotechnology #Comment #Data #Gene editing #Genetics / genomics #Genome sequencing #Healthcare #Public health #Research #Whole genome sequencing

Why genomic healthcare data matters in the development of new therapies 

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies - precision medicines. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact.  The origins  One might argue that this all started… Read More

#Exclusive Content #Opinion #Trends & Analysis

Japanese flag
#Biopharmaceutical #Collaboration #Drug discovery #Healthcare #Investment #Life sciences #Market reporting #Start-ups

A review of Japan’s drug discovery landscape  

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world, despite what the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #Trends & Analysis

#AI / data analytics / healthtech / informatics #Biopharmaceuticals #Drug discovery #Healthcare

How AI in pharma can live up to the hype 

Listen to this article on the DDW Podcast: Ben Folwell, Principal Consultant at Citeline, maps out how AI, swarm learning and open access to clinical data could revolutionise drug discovery.  Artificial intelligence (AI) is notorious for its industry hype, touted to revolutionise the way multiple sectors operate over the next five… Read More

#Business & Investment #Exclusive Content #Opinion #Trends & Analysis